Stephanie Lee

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. pmc Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia
    Stephanie J Lee
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 112:3500-7. 2008
  2. ncbi request reprint Quality of life associated with acute and chronic graft-versus-host disease
    S J Lee
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Bone Marrow Transplant 38:305-10. 2006
  3. pmc Providing personalized prognostic information for adult leukemia survivors
    Stephanie J Lee
    Fred Hutchinson Cancer Research Center, Seattle, Washington Electronic address
    Biol Blood Marrow Transplant 19:1600-7. 2013
  4. pmc Poor agreement between clinician response ratings and calculated response measures in patients with chronic graft-versus-host disease
    Jeanne M Palmer
    Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226
    Biol Blood Marrow Transplant 18:1649-55. 2012
  5. pmc Acute graft versus host disease after orthotopic liver transplantation
    Inga Mandac Rogulj
    University of Zagreb School of Medicine, University Hospital Merkur, Zagreb, Croatia
    J Hematol Oncol 5:50. 2012
  6. doi request reprint Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study
    Stephanie J Lee
    Dana Farber Cancer Institute, Boston, MA, USA
    Br J Haematol 143:511-9. 2008
  7. doi request reprint Patient-reported outcomes for acute graft-versus-host disease prevention and treatment trials
    Stephanie J Lee
    Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 16:295-300. 2010
  8. pmc Frequency of abnormal findings detected by comprehensive clinical evaluation at 1 year after allogeneic hematopoietic cell transplantation
    Stephanie J Lee
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 15:416-20. 2009
  9. doi request reprint Individual physician practice variation in hematopoietic cell transplantation
    Stephanie J Lee
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D5 290, Seattle, WA 98109, USA
    J Clin Oncol 26:2162-70. 2008
  10. pmc Variation in supportive care practices in hematopoietic cell transplantation
    Stephanie J Lee
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 14:1231-8. 2008

Research Grants

  1. Enhancing Doctor-Patient Communication
    Stephanie Lee; Fiscal Year: 2003
  2. Enhancing Doctor-Patient Communication
    Stephanie Lee; Fiscal Year: 2004
  3. Enhancing Doctor-Patient Communication
    Stephanie Lee; Fiscal Year: 2005
  4. Enhancing Doctor-Patient Communication
    Stephanie Lee; Fiscal Year: 2006
  5. Enhancing Doctor-Patient Communication
    Stephanie Lee; Fiscal Year: 2005
  6. Improving Outcomes Assessment in Chronic GVHD
    Stephanie Lee; Fiscal Year: 2007
  7. Core--Data Management and Specimen Tracking
    Stephanie Lee; Fiscal Year: 2007

Detail Information

Publications80

  1. pmc Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia
    Stephanie J Lee
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 112:3500-7. 2008
    ..Acute graft-versus-host disease rates were similar between IM(+) and IM(-) groups regardless of leukemia phase. These results should be reassuring to patients receiving IM before HCT...
  2. ncbi request reprint Quality of life associated with acute and chronic graft-versus-host disease
    S J Lee
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Bone Marrow Transplant 38:305-10. 2006
    ..The adverse effects of acute GVHD are detectable with the TOI at 6 months post transplantation after which development of chronic GVHD is the most strongly correlated with worse QOL...
  3. pmc Providing personalized prognostic information for adult leukemia survivors
    Stephanie J Lee
    Fred Hutchinson Cancer Research Center, Seattle, Washington Electronic address
    Biol Blood Marrow Transplant 19:1600-7. 2013
    ..cibmtr.org/LeukemiaCalculators). This prognostic information is more relevant for survivors than estimates provided before transplantation. ..
  4. pmc Poor agreement between clinician response ratings and calculated response measures in patients with chronic graft-versus-host disease
    Jeanne M Palmer
    Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226
    Biol Blood Marrow Transplant 18:1649-55. 2012
    ....
  5. pmc Acute graft versus host disease after orthotopic liver transplantation
    Inga Mandac Rogulj
    University of Zagreb School of Medicine, University Hospital Merkur, Zagreb, Croatia
    J Hematol Oncol 5:50. 2012
    ..However, success rates have been low, and new approaches are needed...
  6. doi request reprint Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study
    Stephanie J Lee
    Dana Farber Cancer Institute, Boston, MA, USA
    Br J Haematol 143:511-9. 2008
    ..These results show that bortezomib was associated with significantly better multidimensional HRQL compared with dexamethasone, consistent with the better clinical outcomes seen with bortezomib...
  7. doi request reprint Patient-reported outcomes for acute graft-versus-host disease prevention and treatment trials
    Stephanie J Lee
    Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 16:295-300. 2010
    ..This article summarizes issues to be considered in the use of PROs as endpoints in aGVHD prevention and treatment trials...
  8. pmc Frequency of abnormal findings detected by comprehensive clinical evaluation at 1 year after allogeneic hematopoietic cell transplantation
    Stephanie J Lee
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 15:416-20. 2009
    ..Longer follow-up is needed to determine whether early detection and intervention affect later morbidity and mortality...
  9. doi request reprint Individual physician practice variation in hematopoietic cell transplantation
    Stephanie J Lee
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D5 290, Seattle, WA 98109, USA
    J Clin Oncol 26:2162-70. 2008
    ..Previous studies have evaluated practice variation in hematopoietic cell transplantation (HCT) among transplant centers and countries. There are no studies investigating individual physician practice variation in HCT...
  10. pmc Variation in supportive care practices in hematopoietic cell transplantation
    Stephanie J Lee
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 14:1231-8. 2008
    ..For practices proved to be beneficial, publication of guidelines and incorporation of monitoring into quality improvement initiatives may help standardize practices...
  11. pmc Have we made progress in the management of chronic graft-vs-host disease?
    Stephanie J Lee
    University of Washington, Seattle, 98109, United States
    Best Pract Res Clin Haematol 23:529-35. 2010
    ..These consensus documents will help to standardize efforts and data collection so that true comparisons can be made in the future and real clinical progress achieved...
  12. doi request reprint Tips for writing successful patient-oriented research career development awards
    Stephanie J Lee
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Hematology Am Soc Hematol Educ Program 2010:185-8. 2010
    ..This area of research includes: 1) mechanisms of human disease; 2) therapeutic interventions; 3) clinical trials, and; 4) the development of new technologies."..
  13. ncbi request reprint High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation
    Stephanie J Lee
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 110:4576-83. 2007
    ..High-resolution DNA matching for HLA-A, -B, -C, and -DRB1 alleles is associated with higher rates of survival...
  14. pmc Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease
    Mary E D Flowers
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 14:1380-4. 2008
    ..Other measures of clinical benefit, such as response, will need to be developed as endpoints in phase II trials for patients with cGVHD...
  15. pmc Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes
    Marco Mielcarek
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 113:2888-94. 2009
    ..We conclude that initial treatment with low-dose glucocorticoids for patients with grades I-II GVHD did not compromise disease control or mortality and was associated with decreased toxicity...
  16. ncbi request reprint A phase 2 study of bortezomib in relapsed, refractory myeloma
    Paul G Richardson
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    N Engl J Med 348:2609-17. 2003
    ..Bortezomib, a boronic acid dipeptide, is a novel proteasome inhibitor that has been shown in preclinical and phase 1 studies to have antimyeloma activity...
  17. ncbi request reprint Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease
    Daniel J DeAngelo
    Dana Farber Cancer Institute, Department of Adult Oncology, Boston, Massachusetts 02115, USA
    Clin Cancer Res 10:5065-71. 2004
    ..Recent reports indicate that imatinib mesylate (Gleevec) can induce remissions in these patients as well. Less is known about the extent and durability of these responses...
  18. pmc Double unrelated reduced-intensity umbilical cord blood transplantation in adults
    Karen K Ballen
    Division of Hematology Oncology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Biol Blood Marrow Transplant 13:82-9. 2007
    ..Our findings indicate that adult patients can tolerate double UBC transplantation well and achieve sustained antitumor responses using this reduced-intensity conditioning regimen...
  19. ncbi request reprint Routine screening for psychosocial distress following hematopoietic stem cell transplantation
    S J Lee
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Bone Marrow Transplant 35:77-83. 2005
    ..Pre-transplant distress appears to be highly predictive of distress post transplant and is a feasible marker to target screening and intervention programs...
  20. ncbi request reprint Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy
    A M Saito
    Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Bone Marrow Transplant 40:209-17. 2007
    ..Our data suggest that substantially lower costs and fewer days of hospitalization within the first year after RICT procedures can be obtained with no compromise of long-term clinical outcomes compared to HDCT procedures...
  21. ncbi request reprint Recovery after stem-cell transplantation for hematologic diseases
    S J Lee
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 19:242-52. 2001
    ....
  22. ncbi request reprint Predicting costs of stem-cell transplantation
    S J Lee
    Department of Adult Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 18:64-71. 2000
    ..We sought (1) to determine whether obtaining baseline information enabled identification of patients whose treatments would be the most costly and (2) to estimate inpatient costs for managing specific transplantation complications...
  23. ncbi request reprint Pre-transplantation physical and mental functioning is strongly associated with self-reported recovery from stem cell transplantation
    D J Andorsky
    Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Bone Marrow Transplant 37:889-95. 2006
    ..Measurement of baseline QOL can help place the effects of the transplantation procedure in context...
  24. ncbi request reprint Chronic myelogenous leukaemia
    S J Lee
    Center for Outcomes and Policy Research, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Br J Haematol 111:993-1009. 2000
    ..Clinical and laboratory science seems poised to add novel therapies to the armamentarium against CML. It is exciting to contemplate what reviews of CML written 10 years from now will discuss...
  25. ncbi request reprint Partial CD8+ T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease
    V T Ho
    Department of Medical Oncology, Biostatistics, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Bone Marrow Transplant 34:987-94. 2004
    ..There was no correlation between CD8+ number and GVHD or survival. A 2-log depletion of CD8+ cells from PBSC is insufficient to prevent GVHD...
  26. ncbi request reprint Discrepancies between patient and physician estimates for the success of stem cell transplantation
    S J Lee
    Center for Outcomes and Policy Research, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    JAMA 285:1034-8. 2001
    ..Stem cell transplantation is associated with considerable morbidity and mortality. The extent to which patients and their physicians correctly estimate these risks is unknown...
  27. ncbi request reprint Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation
    V T Ho
    Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 7:223-9. 2001
    ..Patients with pretransplantation FEV1 of < or = 80% appear to have a higher risk for SPCs...
  28. ncbi request reprint A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation
    J H Antin
    Department of Adult Oncology and Biostatistical Science, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Bone Marrow Transplant 29:373-7. 2002
    ..The use of IL-11 as GVHD prophylaxis in allogeneic transplantation cannot be recommended as administered in this trial...
  29. ncbi request reprint Role of skin biopsy to confirm suspected acute graft-vs-host disease: results of decision analysis
    Bahar F Firoz
    Department of Dermatology, New York University, New York, USA
    Arch Dermatol 142:175-82. 2006
    ..To estimate the value of skin biopsy in the evaluation of suspected acute cutaneous graft-vs-host disease (GVHD) after allogeneic stem cell transplantation...
  30. ncbi request reprint Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report
    Steven Z Pavletic
    National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1203, USA
    Biol Blood Marrow Transplant 12:252-66. 2006
    ..The proposed response criteria are based on current expert consensus opinion and are intended to improve consistency in the conduct and reporting of chronic GVHD trials, but their use remains to be demonstrated in practice...
  31. ncbi request reprint Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Res
    J Douglas Rizzo
    Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
    Biol Blood Marrow Transplant 12:138-51. 2006
    ....
  32. ncbi request reprint Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working
    Daniel Couriel
    University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Biol Blood Marrow Transplant 12:375-96. 2006
    ..Optimal care of patients with chronic GVHD often requires a multidisciplinary approach...
  33. pmc Costs of allogeneic hematopoietic cell transplantation with high-dose regimens
    Akiko M Saito
    Division of Medical Oncology, Dana Farber Cancer Institute, and Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Biol Blood Marrow Transplant 14:197-207. 2008
    ..If no complications occurred, the mean cost within the first year was $79,222. These results provide cost estimates for complicated and uncomplicated HDCT procedures, as well as costs for management of specific transplant complications...
  34. ncbi request reprint National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report
    Paul J Martin
    Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, Washington 98109 1024, USA, and Hopital St Louis, Paris, France
    Biol Blood Marrow Transplant 12:491-505. 2006
    ..The use of consistent standards in clinical trial designs to evaluate agents that have activity in pathogenic pathways could facilitate advances in the treatment of chronic GVHD...
  35. ncbi request reprint Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia
    Jennifer R Brown
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 12:1056-64. 2006
    ....
  36. ncbi request reprint End points to establish the efficacy of new agents in the treatment of acute leukemia
    Frederick R Appelbaum
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 109:1810-6. 2007
    ..In this report, we present the results of that effort...
  37. ncbi request reprint Advance care planning in patients undergoing hematopoietic cell transplantation
    Steven Joffe
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 13:65-73. 2007
    ..Even though ACP was more prevalent among this sample than in the general population, its use still could be enhanced, given the high risks of decisional incapacity and death that HCT patients face...
  38. ncbi request reprint Transplantation's greatest challenges: advances in chronic graft-versus-host disease
    Warren D Shlomchik
    Department of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut, USA
    Biol Blood Marrow Transplant 13:2-10. 2007
    ..In this overview, we address 3 key areas related to chronic GVHD that hold the highest promise for major advances in the near future: pathobiology, response criteria, and therapy...
  39. ncbi request reprint Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia
    Sergio A Giralt
    M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77230, USA
    Br J Haematol 137:461-7. 2007
    ..Most patients now receive a trial of imatinib before proceeding to HCT...
  40. ncbi request reprint Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report
    Kirk R Schultz
    British Columbia Children s Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    Biol Blood Marrow Transplant 12:126-37. 2006
    ..Both approaches have merit and should be pursued. The consistent treatment and standardized documentation needed to support biomarker studies are most likely to be satisfied in prospective clinical trials...
  41. ncbi request reprint Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report
    Howard M Shulman
    Department of Pathology, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, University of Washington School of Medicine, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 12:31-47. 2006
    ..Consensus recommendations and suggested data-capture forms should be validated in prospective clinicopathologic studies...
  42. ncbi request reprint Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs
    Stephanie J Lee
    Department of Adult Oncology and Department of Biostatistical Science, Dana Farber Cancer Institute, and the Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Blood 100:2697-702. 2002
    ..As prospective, randomized studies comparing methods of GVHD prophylaxis are performed, assessment of quality of life and costs should be included to fully understand the overall impact of each intervention...
  43. ncbi request reprint Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial
    Stephanie J Lee
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 104:1559-64. 2004
    ..002). Both relapse- and GVHD-related mortality contributed to the increased mortality in the combination group. The combination of corticosteroids and daclizumab should not be used as initial therapy of acute GVHD...
  44. ncbi request reprint Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
    Vincent T Ho
    Dana Farber Cancer Institute, 44 Binney St, D1B21, Boston, MA 02115, USA
    Blood 104:1224-6. 2004
    ..Eight of 24 patients (33%) are alive at 6.3 to 24.6 months (median, 7.2 months). Denileukin diftitox is tolerable and has promising activity in steroid-refractory acute GVHD...
  45. ncbi request reprint Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation
    Corey Cutler
    Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 10:328-36. 2004
    ..Mucositis was modest, engraftment was prompt, and transplant-related toxicity was modest. Methotrexate-free, sirolimus-based GVHD prophylactic regimens should be tested in randomized trials against the current standard of care...
  46. ncbi request reprint Trends in survival rates after allogeneic hematopoietic stem-cell transplantation for acute and chronic leukemia by ethnicity in the United States and Canada
    Derek S Serna
    Department of Internal Medicine, Health Policy Institute, Medical College of Wisconsin Milwaukee, WI 53226, USA
    J Clin Oncol 21:3754-60. 2003
    ..Differences in survival among ethnic groups in the United States are reported in numerous diseases and treatment strategies. Whether survival after allogeneic hematopoietic stem-cell transplantation (HSCT) differs by ethnicity is uncertain...
  47. ncbi request reprint Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study
    Francisco M Marty
    Division of Infectious Diseases and Hematopoietic Stem Cell Transpalntation Service, Brigham and Women s Hospital and Dana Farber Cancer Instiute, Harvard Medical School, Boston, MA 02115, USA
    Blood 102:2768-76. 2003
    ..Pre-emptive systemic antifungal therapy against molds should be considered in patients who develop severe GVHD after HSCT if infliximab is used...
  48. ncbi request reprint Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation
    Martha Wadleigh
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 102:1578-82. 2003
    ..Three of 14 patients who received GO prior to SC transplantation died of VOD. We conclude that patients undergoing SC transplantation within a short interval from GO administration are at increased risk of developing VOD...
  49. ncbi request reprint Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation
    Joseph H Antin
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 102:1601-5. 2003
    ..This novel agent is worthy of further study in allogeneic transplantation...
  50. ncbi request reprint Chronic graft-versus-host disease
    Stephanie J Lee
    Department of Adult Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 9:215-33. 2003
    ..It also provides a comprehensive listing of the published clinical trials aimed at prevention and primary treatment of chronic GVHD...
  51. ncbi request reprint Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation
    Joseph H Antin
    Department of Medical Oncology and Biostatistical Science, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 100:3479-82. 2002
    ..We conclude that blockade of IL-1 using IL-1Ra during conditioning and 10 days immediately after transplantation is not sufficient to reduce GVHD or toxicity or to improve survival...
  52. ncbi request reprint Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse
    Stephanie J Lee
    Graft vs Host Disease Working Committee of the International Bone Marrow Transplant Registry, Health Policy Institute, Medical College of Wisconsin, Milwaukee, WI, USA
    Blood 100:406-14. 2002
    ..Survival and disease-free survival of the most favorable cGVHD group in each scheme were similar, or better, than those of patients without cGVHD; these patients may not need aggressive or extended immune suppression...
  53. ncbi request reprint Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age
    Edwin P Alyea
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Blood 105:1810-4. 2005
    ..052). Our experience suggests that, in patients over age 50, NST with fludarabine and low-dose busulfan leads to an overall outcome at least as good as that following myeloablative therapy...
  54. pmc Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission
    David B Miklos
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, M530, Boston, MA 02115, USA
    Blood 105:2973-8. 2005
    ..Antibody response to Y-chromosome encoded histocompatibility antigens (H-Y antigens) was also associated with maintenance of disease remission (P < .0001). B cells may provide a new target for immune intervention in chronic GVHD...
  55. ncbi request reprint A survey of diagnosis, management, and grading of chronic GVHD
    Stephanie J Lee
    Center for Outcomes and Policy Research, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 8:32-9. 2002
    ..We conclude that studies defining appropriate diagnostic pathways, criteria for disease activity, and prognosis could help standardize management of cGVHD. There is an urgent need to develop and test new approaches to treat cGVHD...
  56. pmc Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease
    Emmanuel Zorn
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 106:2903-11. 2005
    ..These findings support the development of new strategies to increase the number of Tregs following allogeneic hematopoietic stem cell transplantation to prevent or correct cGVHD...
  57. pmc Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) pros
    Jean Yves Cahn
    Department of Onco Hematology, Hopital Michallon, Centre Hospitalo Universitaire, INSERM EMI 353, 38700 Grenoble Cedex 9, France
    Blood 106:1495-500. 2005
    ..Validity of these results in populations receiving peripheral blood transplants or nonmyeloablative conditioning regimens remains to be tested...
  58. ncbi request reprint Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation
    Corey Cutler
    Department of Medical Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 11:551-7. 2005
    ..A careful monitoring strategy for TMA should be used with a sirolimus-containing graft-versus-host disease prophylaxis regimen...
  59. ncbi request reprint National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report
    Alexandra H Filipovich
    Cincinnati Children s Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio 45229, USA
    Biol Blood Marrow Transplant 11:945-56. 2005
    ..It is currently recommended that systemic therapy be considered for patients who meet criteria for chronic GVHD of moderate to severe global severity...
  60. ncbi request reprint Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens
    Corey Cutler
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 11:383-8. 2005
    ..Less toxic GVHD prophylaxis regimens without methotrexate may have a significant effect on patient quality of life, patient outcomes, and economic outcomes associated with allogeneic stem cell transplantation...
  61. pmc New approaches for preventing and treating chronic graft-versus-host disease
    Stephanie J Lee
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 105:4200-6. 2005
    ..Inherent difficulties in conducting human clinical trials also contribute to the lack of meaningful progress. This review covers potential new approaches to the prevention and treatment of chronic GVHD...
  62. ncbi request reprint Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology
    J Douglas Rizzo
    Medical College of Wisconsin, Milwaukee, WI, USA
    J Clin Oncol 20:4083-107. 2002
    ..Therefore, for anemic patients with hematologic malignancies, it is recommended that physicians initiate conventional therapy and observe hematologic response before considering use of epoetin...
  63. ncbi request reprint Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology
    J Douglas Rizzo
    Medical College of Wisconsin, Milwaukee, WI 53226, USA
    Blood 100:2303-20. 2002
    ..Therefore, for anemic patients with hematologic malignancies it is recommended that physicians initiate conventional therapy and observe hematologic response before considering use of epoetin...
  64. ncbi request reprint Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study
    Gorgun Akpek
    Department of Oncology, Johns Hopkins University, Baltimore, MD, USA
    Blood 102:802-9. 2003
    ..Although the new clinical grading based on the model is promising because of its utility across multiple independent data sets, prospective validation is needed...
  65. ncbi request reprint JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance
    Alexandra P Wolanskyj
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 131:208-13. 2005
    ..Therefore, although the presence of JAK2(V617F) in ET appears to promote a PV phenotype, it might not carry treatment-relevant information...
  66. ncbi request reprint Differences in characteristics of US hematopoietic stem cell transplantation centers by proportion of racial or ethnic minorities
    Christopher J Schwake
    Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
    Biol Blood Marrow Transplant 11:988-98. 2005
    ..Our results suggest that the inferior survival reported in ethnic minorities after HSCT may not be readily explained by center effects...
  67. ncbi request reprint Association of depressive syndrome and early deaths among patients after stem-cell transplantation for malignant diseases
    Fausto R Loberiza
    Health Policy Institute and the Department of Medicine, Hematology and Oncology, Bone Marrow Transplantation Program, Medical College of Wisconsin, Milwaukee, WI 53224, USA
    J Clin Oncol 20:2118-26. 2002
    ..However, depression is not well studied in the setting of hematopoietic stem-cell transplantation (HSCT). We examined the association between depressive syndrome and survival after HSCT...
  68. ncbi request reprint The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera
    Ayalew Tefferi
    Division of Hematology and Laboratory Medicine, Mayo Clinic, Rochester, Minnesota 55905, and Department of Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Cancer 106:631-5. 2006
    ..Several studies have recently reported on the occurrence of a JAK2(V617F) mutation in myeloid cells from the majority of patients with polycythemia vera (PV). The clinical relevance of this novel observation currently is under study...
  69. ncbi request reprint Optimistic expectations and survival after hematopoietic stem cell transplantation
    Stephanie J Lee
    Department of Medical Oncology, and Center for Outcomes and Policy Research, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 9:389-96. 2003
    ..Our data suggest an association between more optimistic expectations and early survival following hematopoietic stem cell transplantation, but this association is not present by 6 months posttransplantation...
  70. ncbi request reprint Physicians' attitudes about quality-of-life issues in hematopoietic stem cell transplantation
    Stephanie J Lee
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 104:2194-200. 2004
    ....
  71. ncbi request reprint Direct-to-consumer advertising in oncology: a content analysis of print media
    Gregory A Abel
    Center for Outcomes and Policy Research, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 25:1267-71. 2007
    ..Content analysis of cancer-related direct-to-consumer advertising (DTCA), with a focus on how benefit and risk/adverse effect information is presented, is essential to understanding its potential impact on oncology outcomes...
  72. pmc MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia
    Yana Pikman
    Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS Med 3:e270. 2006
    ....
  73. ncbi request reprint Sentinel lymph node biopsy for evaluation and treatment of patients with Merkel cell carcinoma: The Dana-Farber experience and meta-analysis of the literature
    Sheela G Gupta
    Cutaneous Oncology Disease Center, Dana Farber Brigham and Women s Cancer Center, Boston, Mass, USA
    Arch Dermatol 142:685-90. 2006
    ..To determine the diagnostic accuracy and usefulness of sentinel lymph node biopsy (SLNB) and computed tomographic scans in the initial evaluation and treatment of patients with Merkel cell carcinoma (MCC)...
  74. ncbi request reprint Outcomes after hematopoietic stem-cell transplantation for hematologic malignancies in patients with or without advance care planning
    Apar Kishor Ganti
    University of Nebraska Medical Center, Section of Oncology Hematology, 987680 Nebraska Medical Center, Omaha, NE 68198 7680, USA
    J Clin Oncol 25:5643-8. 2007
    ..We conducted this analysis to determine if engagement in ACP among patients who undergo HSCT is associated with adverse outcomes...
  75. ncbi request reprint Clinical evaluation of oral chronic graft-versus-host disease
    Nathaniel S Treister
    Division of Oral and Maxillofacial Surgery, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 14:110-5. 2008
    ....
  76. ncbi request reprint A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome
    Corey S Cutler
    International Bone Marrow Transplant Registry, Medical College of Wisconsin, 8701 Watertown Plank Rd, PO Box 26509, Milwaukee, WI 53226, USA
    Blood 104:579-85. 2004
    ..For low- and intermediate-1-risk MDS, delayed BMT is associated with maximal life expectancy, whereas immediate transplantation for intermediate-2- and high-risk disease is associated with maximal life expectancy...
  77. pmc Chronic Graft-versus-Host Disease--implementation of the National Institutes of Health Consensus Criteria for Clinical Trials
    Linda M Griffith
    Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Biol Blood Marrow Transplant 14:379-84. 2008
  78. pmc Rituximab for steroid-refractory chronic graft-versus-host disease
    Corey Cutler
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 108:756-62. 2006
    ..We conclude that specific anti-B-cell therapy with rituximab may be beneficial for patients with steroidrefractory chronic GVHD. This trial was registered at www.clinicaltrials.gov as #NCT00136396...
  79. ncbi request reprint Association of transplant center and physician factors on mortality after hematopoietic stem cell transplantation in the United States
    Fausto R Loberiza
    University of Nebraska Medical Center, Center for International Blood and Marrow Transplant Research CIBMTR, Medical College of Wisconsin, Milwaukee, WI, USA
    Blood 105:2979-87. 2005
    ..Greater physician involvement in patient care is important in producing favorable outcomes after HSCT. To more clearly establish the role of the factors we identified, further studies are recommended...

Research Grants8

  1. Enhancing Doctor-Patient Communication
    Stephanie Lee; Fiscal Year: 2003
    ..The project works towards the overall goal of enhancing communication, improving patient understanding, and facilitating psychosocial adaptation to life-threatening illness. ..
  2. Enhancing Doctor-Patient Communication
    Stephanie Lee; Fiscal Year: 2004
    ..The project works towards the overall goal of enhancing communication, improving patient understanding, and facilitating psychosocial adaptation to life-threatening illness. ..
  3. Enhancing Doctor-Patient Communication
    Stephanie Lee; Fiscal Year: 2005
    ..The project works towards the overall goal of enhancing communication, improving patient understanding, and facilitating psychosocial adaptation to life-threatening illness. ..
  4. Enhancing Doctor-Patient Communication
    Stephanie Lee; Fiscal Year: 2006
    ..The project works towards the overall goal of enhancing communication, improving patient understanding, and facilitating psychosocial adaptation to life-threatening illness. ..
  5. Enhancing Doctor-Patient Communication
    Stephanie Lee; Fiscal Year: 2005
    ..The project works towards the overall goal of enhancing communication, improving patient understanding, and facilitating psychosocial adaptation to life-threatening illness. ..
  6. Improving Outcomes Assessment in Chronic GVHD
    Stephanie Lee; Fiscal Year: 2007
    ..These studies are needed to operationalize the recommendations of the NIH Consensus conference, advance our understanding of chronic GVHD, and enhance our ability to conduct clinical trials. ..
  7. Core--Data Management and Specimen Tracking
    Stephanie Lee; Fiscal Year: 2007
    ..3. To provide a central mechanism for specimen collection, identification and tracking between the three projects. 4. To provide data management support and quality control for clinical data. ..